Analyzing Deciphera Pharmaceuticals (DCPH) & Stemline Therapeutics (STML)

Deciphera Pharmaceuticals (NASDAQ: DCPH) and Stemline Therapeutics (NASDAQ:STML) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Deciphera Pharmaceuticals and Stemline Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Deciphera Pharmaceuticals N/A N/A -$25.94 million N/A N/A
Stemline Therapeutics $1.04 million 321.12 -$38.30 million ($2.45) -5.43

Deciphera Pharmaceuticals has higher revenue, but lower earnings than Stemline Therapeutics.

Insider and Institutional Ownership

2.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 48.4% of Stemline Therapeutics shares are held by institutional investors. 15.7% of Stemline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Deciphera Pharmaceuticals and Stemline Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Deciphera Pharmaceuticals 0 0 5 0 3.00
Stemline Therapeutics 0 0 6 0 3.00

Deciphera Pharmaceuticals presently has a consensus target price of $43.40, indicating a potential upside of 128.90%. Stemline Therapeutics has a consensus target price of $33.40, indicating a potential upside of 151.13%. Given Stemline Therapeutics’ higher possible upside, analysts plainly believe Stemline Therapeutics is more favorable than Deciphera Pharmaceuticals.

Profitability

This table compares Deciphera Pharmaceuticals and Stemline Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Deciphera Pharmaceuticals N/A N/A N/A
Stemline Therapeutics -4,176.84% -67.35% -58.14%

Summary

Stemline Therapeutics beats Deciphera Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

What are top analysts saying about Deciphera Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Deciphera Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit